Alexandra James

928 total citations
20 papers, 634 citations indexed

About

Alexandra James is a scholar working on Epidemiology, Genetics and Surgery. According to data from OpenAlex, Alexandra James has authored 20 papers receiving a total of 634 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Epidemiology, 16 papers in Genetics and 4 papers in Surgery. Recurrent topics in Alexandra James's work include Inflammatory Bowel Disease (16 papers), Microscopic Colitis (15 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (3 papers). Alexandra James is often cited by papers focused on Inflammatory Bowel Disease (16 papers), Microscopic Colitis (15 papers) and Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (3 papers). Alexandra James collaborates with scholars based in United States, Canada and United Kingdom. Alexandra James's co-authors include Brihad Abhyankar, Karen Lasch, Roslyn B. Mannon, Brian G. Feagan, David T. Rubin, Bruce E. Sands, Silvio Danese, Serap Sankoh, Michael Smyth and Séverine Vermeire and has published in prestigious journals such as Gastroenterology, Annals of the Rheumatic Diseases and The American Journal of Gastroenterology.

In The Last Decade

Alexandra James

17 papers receiving 621 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alexandra James United States	10	456	409	171	130	86	20	634
Soo-Kyung Park South Korea	10	277 0.6×	211 0.5×	171 1.0×	107 0.8×	72 0.8×	22	727
Philippe Godeberge France	13	346 0.8×	297 0.7×	315 1.8×	71 0.5×	18 0.2×	25	687
Gilbert Tucat France	7	429 0.9×	365 0.9×	184 1.1×	60 0.5×	44 0.5×	26	591
Adriaan A. van Bodegraven Netherlands	11	291 0.6×	208 0.5×	226 1.3×	124 1.0×	56 0.7×	29	554
Dirk Demuth United States	9	320 0.7×	279 0.7×	113 0.7×	78 0.6×	26 0.3×	42	453
Gianluca Andrisani Italy	15	390 0.9×	346 0.8×	220 1.3×	136 1.0×	130 1.5×	48	721
Sarah Persing United States	11	362 0.8×	282 0.7×	404 2.4×	78 0.6×	19 0.2×	42	822
Toshihiro Bando Japan	15	350 0.8×	285 0.7×	326 1.9×	35 0.3×	24 0.3×	42	585
Kristin Kaasen Jørgensen Norway	14	218 0.5×	271 0.7×	185 1.1×	126 1.0×	135 1.6×	35	577
R. J. Farrell United States	7	148 0.3×	124 0.3×	147 0.9×	52 0.4×	118 1.4×	17	479

Countries citing papers authored by Alexandra James

Since Specialization

Citations

This map shows the geographic impact of Alexandra James's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexandra James with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexandra James more than expected).

Fields of papers citing papers by Alexandra James

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexandra James. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexandra James. The network helps show where Alexandra James may publish in the future.

Co-authorship network of co-authors of Alexandra James

This figure shows the co-authorship network connecting the top 25 collaborators of Alexandra James. A scholar is included among the top collaborators of Alexandra James based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexandra James. Alexandra James is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Allanore, Yannick, Madelon C Vonk, Oliver Distler, et al.. (2025). Continued nintedanib in patients with systemic sclerosis-associated interstitial lung disease: 3-year data from SENSCIS-ON. RMD Open. 11(1). e005086–e005086. 1 indexed citations

Colombel, Jean‐Frédéric, Ryan C. Ungaro, Bruce E. Sands, et al.. (2023). Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn’s Disease (EXPLORER). Clinical Gastroenterology and Hepatology. 22(7). 1487–1496.e12. 49 indexed citations

Jairath, Vipul, Andrés Yarur, Mark T. Osterman, et al.. (2023). ENTERPRET: A Randomized Controlled Trial of Vedolizumab Dose Optimization in Patients With Ulcerative Colitis Who Have Early Nonresponse. Clinical Gastroenterology and Hepatology. 22(5). 1077–1086.e13. 17 indexed citations

Osterman, Mark T., Vipul Jairath, Alexandra James, et al.. (2022). 791: A RANDOMIZED TRIAL OF VEDOLIZUMAB DOSE OPTIMIZATION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS WHO HAVE EARLY NONRESPONSE AND HIGH DRUG CLEARANCE: THE ENTERPRET TRIAL. Gastroenterology. 162(7). S–190. 11 indexed citations

Allanore, Yannick, Madelon C Vonk, Oliver Distler, et al.. (2022). Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON. Annals of the Rheumatic Diseases. 81(12). 1722–1729. 24 indexed citations

Matteson, Eric L., Clive Kelly, Jörg H. W. Distler, et al.. (2022). Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial. Arthritis & Rheumatology. 74(6). 1039–1047. 65 indexed citations

Colombel, Jean‐Frédéric, Ryan C. Ungaro, Bruce E. Sands, et al.. (2022). 885: TRIPLE COMBINATION THERAPY WITH VEDOLIZUMAB, ADALIMUMAB, AND METHOTREXATE IN PATIENTS WITH HIGH-RISK CROHN'S DISEASE: INTERIM ANALYSIS FROM THE OPEN-LABEL, PHASE 4 EXPLORER TRIAL. Gastroenterology. 162(7). S–215. 4 indexed citations

Osterman, Mark T., et al.. (2020). P065 CHARACTERIZATION OF EARLY CLINICAL AND PHARMACOKINETIC RESPONSE PROFILES OF VEDOLIZUMAB: AN INTERIM ANALYSIS OF ENTERPRET, A PHASE 4 CLINICAL STUDY. Inflammatory Bowel Diseases. 26(Supplement_1). S9–S9.

Osterman, Mark T., Andrés Yarur, Udayakumar Navaneethan, et al.. (2020). P065 CHARACTERIZATION OF EARLY CLINICAL AND PHARMACOKINETIC RESPONSE PROFILES OF VEDOLIZUMAB: AN INTERIM ANALYSIS OF ENTERPRET, A PHASE 4 CLINICAL STUDY. Gastroenterology. 158(3). S15–S15.

10.

Feagan, Brian G., Stefan Schreiber, Douglas C. Wolf, et al.. (2018). Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis. Inflammatory Bowel Diseases. 25(6). 1028–1035. 21 indexed citations

11.

Cao, Charlie, et al.. (2018). Vedolizumab Demonstrates Early Symptomatic Improvement in Ulcerative Colitis: A GEMINI 1 Post Hoc Analysis. The American Journal of Gastroenterology. 113. S24–S24. 3 indexed citations

12.

Yajnik, Vijay, Nabeel Khan, Marla C. Dubinsky, et al.. (2017). Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age. Advances in Therapy. 34(2). 542–559. 68 indexed citations

13.

Feagan, Brian G., Trevor Lissoos, Karen Lasch, et al.. (2017). Vedolizumab Demonstrates Early Symptomatic Improvement in Crohnʼs Disease (CD): A GEMINI 2 Post hoc Analysis. The American Journal of Gastroenterology. 112. S370–S372. 1 indexed citations

14.

Feagan, Brian G., Karen Lasch, Javaria Mona Khalid, et al.. (2017). Vedolizumab Demonstrates Early Symptomatic Improvement in Ulcerative Colitis: A GEMINI 1 Post hoc Analysis. The American Journal of Gastroenterology. 112. S371–S373. 3 indexed citations

15.

Loftus, Edward V., Jean‐Frédéric Colombel, Brian G. Feagan, et al.. (2017). Long-Term Effectiveness and Safety of Vedolizumab in Patients with Ulcerative Colitis: 5-Year Cumulative Exposure of Gemini 1 Completers Rolling into the Gemini Open-Label Extension Study. Gastroenterology. 152(5). S602–S602. 8 indexed citations

16.

Feagan, Brian G., David T. Rubin, Silvio Danese, et al.. (2016). Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. Clinical Gastroenterology and Hepatology. 15(2). 229–239.e5. 158 indexed citations

17.

Sands, Bruce E., William J. Sandborn, Gert Van Assche, et al.. (2016). Vedolizumab as Induction and Maintenance Therapy for Crohnʼs Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. Inflammatory Bowel Diseases. 23(1). 97–106. 135 indexed citations

18.

Rubin, David T., Brian Feagan, Gerald W. Dryden, et al.. (2016). P-105 The Effect of Vedolizumab on Extraintestinal Manifestations in Patients with Crohnʼs Disease in GEMINI 2. Inflammatory Bowel Diseases. 22. S42–S43. 8 indexed citations

19.

Osterman, Mark T., Xavier Roblin, Sarah C. Glover, et al.. (2016). 512 Association of Vedolizumab Drug Concentrations at or Before Week 6 With Remission at Week 14 in Moderately to Severely Active Ulcerative Colitis Patients From GEMINI 1. Gastroenterology. 150(4). S105–S105. 6 indexed citations

20.

James, Alexandra & Roslyn B. Mannon. (2015). The Cost of Transplant Immunosuppressant Therapy: Is This Sustainable?. Current Transplantation Reports. 2(2). 113–121. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact